There are several investigational obesity peptides that could eventually compete with—or in some cases potentially exceed—retatrutide, but none has yet proven superior to retatrutide in a head-to-head human trial.
Also, retatrutide has not been taken off the market. As of September 2026, it has never been commercially approved in the first place. Lilly is still developing it and plans to submit it to the FDA in Q1 2027. In Phase 3 TRIUMPH-1, the 12 mg dose produced an average 28.3% weight loss at 80 weeks, with a subgroup reaching about 30.3% at 104 weeks.
The biggest caution is that these numbers come from different trials, populations, doses, durations, and statistical methods, so they should not be treated as true head-to-head rankings unless the drugs were tested directly against each other.
| Compound | Mechanism | Development status | Representative weight-loss result | How it currently compares |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Approved obesity therapy | 14.9% at 68 weeks | Established benchmark |
| Tirzepatide | GIP + GLP-1 | Approved obesity therapy | ~20.2% at 72 weeks in a direct semaglutide comparison | Stronger established benchmark |
| Survodutide | Glucagon + GLP-1 | Investigational | ~13% at 76 weeks in Phase 3 | Interesting metabolically, but current obesity efficacy trails tirzepatide/retatrutide |
| Retatrutide | GIP + GLP-1 + glucagon | Phase 3; regulatory filing planned | 28.3% at 80 weeks; ~30.3% in a BMI ≥35 extension subgroup at 104 weeks | Current efficacy leader among these late-stage injectable candidates |
| UBT251 | GIP + GLP-1 + glucagon | Phase 2 | Up to 19.7% at 24 weeks | One of the most compelling direct retatrutide challengers |
| Enicepatide / CT-388 | GIP + GLP-1 | Phase 2 | 22.5% placebo-adjusted at 48 weeks | Very strong signal; no plateau reported |
| Petrelintide | Amylin analog | Phase 2 | Up to 10.7% at 42 weeks | More interesting for tolerability and combinations than raw monotherapy efficacy |
| Petrelintide + enicepatide | Amylin + GIP + GLP-1 | Combination development | Not yet enough mature efficacy data | Potential wildcard |
| Zenagamtide / Amycretin | GLP-1 + amylin | Moving into Phase 3 | Up to 14.6% at 36 weeks in type 2 diabetes | Strong next-generation amylin/incretin concept |
| Eloralintide combinations | Amylin ± incretin therapy | Phase 3/combination development | Still emerging | Potential next wave after GLP-1/GIP therapies |
Semaglutide — the GLP-1 benchmark
Semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks in the landmark STEP 1 obesity trial.
Its importance isn’t that it has the highest weight-loss percentage anymore; it’s that semaglutide established GLP-1 therapy as a major obesity-treatment platform.
Positioning:
SEMAGLUTIDE → FOUNDATION
Appetite control • satiety • established GLP-1 therapy
Tirzepatide — the established next step
Tirzepatide activates both GIP and GLP-1 receptors.
Most importantly, it has actually been compared directly with semaglutide. In a randomized obesity trial, average weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide.
That gives us much stronger evidence that adding GIP receptor activity can meaningfully increase efficacy.
Positioning:
TIRZEPATIDE → DUAL POWER
GIP + GLP-1 • stronger established weight-loss efficacy
Retatrutide — currently setting the bar
Retatrutide adds a third receptor:
GIP + GLP-1 + glucagon
In Phase 3 TRIUMPH-1, the 12 mg dose produced 28.3% average weight loss at 80 weeks, while participants with baseline BMI ≥35 in an extension averaged approximately 30.3% at 104 weeks.
Lilly has also reported successful additional Phase 3 trials and says it intends to submit retatrutide to the FDA in Q1 2027.
Positioning:
RETATRUTIDE → TRIPLE AGONIST
GIP + GLP-1 + glucagon • highest late-stage weight-loss signal so far
UBT251 — perhaps the closest direct challenger
UBT251 uses the same three-receptor strategy:
GLP-1 + GIP + glucagon
In its Chinese Phase 2 obesity study, it produced up to 19.7% mean weight loss after only 24 weeks.
The short duration is what makes that number so interesting. We do not yet know whether the curve will continue toward or beyond retatrutide levels.
Positioning:
UBT251 → NEXT TRIPLE THREAT
At this point, this may be the compound I’d watch most closely if your specific question is, “What could eventually beat retatrutide?”
Enicepatide / CT-388 — surprisingly strong dual agonist
Despite targeting only:
GLP-1 + GIP
Roche reported 22.5% placebo-adjusted weight loss at 48 weeks at the highest dose tested, and importantly, the weight-loss curve had not plateaued.
That’s a very strong Phase 2 signal.
Positioning:
ENICEPATIDE → HIGH-EFFICACY DUAL
It becomes even more interesting when combined with an amylin analog.
Petrelintide — the amylin approach
Petrelintide takes a different route by mimicking amylin, a hormone involved in satiety.
As monotherapy it produced up to 10.7% mean weight reduction at 42 weeks, so by itself it currently doesn’t look like a retatrutide replacement.
Where it becomes more compelling is as a combination partner with enicepatide.
That combination essentially creates:
GLP-1 + GIP + amylin
instead of retatrutide’s:
GLP-1 + GIP + glucagon
That could become an important battle between two different three-pathway approaches.
Zenagamtide / Amycretin — GLP-1 + amylin in one molecule
Novo Nordisk’s zenagamtide combines GLP-1 and amylin receptor agonism in a single peptide.
In adults with type 2 diabetes, the highest studied dose produced up to 14.6% weight loss at 36 weeks, and Novo Nordisk is advancing the program into Phase 3.
Because people with diabetes often lose less weight in obesity-drug trials than people without diabetes, its obesity Phase 3 results will be particularly important.
Positioning:
ZENAGAMTIDE → GLP-1 + AMYLIN
Survodutide — a different glucagon strategy
Survodutide combines:
GLP-1 + glucagon
rather than adding GIP.
Phase 3 SYNCHRONIZE-1 reported substantial weight reduction over 76 weeks, but its current obesity efficacy does not appear competitive with the highest-dose retatrutide results.
Its long-term value may be broader than simple scale weight, particularly because glucagon biology is also being investigated for effects on energy expenditure and metabolic liver disease.
Positioning:
SURVODUTIDE → METABOLIC / GLUCAGON PATHWAY
The evolution is becoming pretty clear
You can think of the field like this:
SEMAGLUTIDE
GLP-1
⬇
TIRZEPATIDE
GLP-1 + GIP
⬇
RETATRUTIDE / UBT251
GLP-1 + GIP + glucagon
Meanwhile, another branch is developing:
AMYLIN
⬇
PETRELINTIDE
⬇
ZENAGAMTIDE — GLP-1 + amylin
⬇
PETRELINTIDE + ENICEPATIDE — amylin + GLP-1 + GIP
That amylin-versus-glucagon pathway competition may be one of the biggest stories in obesity-drug development over the next few years.
Current research ranking for weight-loss potential
Based on the evidence available today, rather than assuming future success:
1. Retatrutide — ~28.3% at 80 weeks
Current late-stage benchmark.
2. UBT251 — 19.7% at only 24 weeks
Potentially the most exciting direct challenger, but much earlier-stage.
3. Enicepatide — 22.5% placebo-adjusted at 48 weeks
One of the strongest emerging dual agonists.
4. Tirzepatide — ~20%+
The strongest established, approved benchmark in this comparison.
5. Petrelintide + enicepatide
Potential could be substantial, but we need mature combination data.
6. Zenagamtide
Very promising mechanistically, with Phase 3 needed to determine its ceiling.
7. Semaglutide — ~15%
Extremely important clinically, but newer multi-receptor agents have raised the efficacy ceiling.
8. Survodutide
Currently more compelling as a broader metabolic/glucagon drug than as a candidate to beat retatrutide on raw weight loss.
One correction to the original premise is important: retatrutide has not been “taken off the market.” It isn’t commercially approved yet. Lilly’s current plan is to seek FDA approval beginning in Q1 2027.
For a Command Fitness graphic, I’d title this:
BEYOND GLP-1: THE NEXT GENERATION OF WEIGHT-LOSS PEPTIDE RESEARCH
Semaglutide → Tirzepatide → Retatrutide → What’s Next?
Then spotlight UBT251, enicepatide, zenagamtide, petrelintide combinations, and survodutide as the emerging contenders rather than saying any has already proven it can outperform retatrutide.